Back to News
Market Impact: 0.25
Janel Corporation Acquires EnCor Biotechnology Inc. for $11,960,000 in Cash and $5,040,000 Promissory Note
Source: Nasdaq
M&A & RestructuringHealthcare & Biotech
On October 20, 2026, Janel Corporation, through wholly owned subsidiary Antibodies Incorporated, agreed to acquire 100% of EnCor Biotechnology Inc.’s issued and outstanding common shares. The provided article text gives no purchase price or other transaction terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Instacart explores potential sale, holds talks with Uber and DoorDash: report
- Europe Hits the Brakes as China’s EV Machine Scales Up